Machine Learning

The deal merges digital orchestration with field AI, promising pharma a unified, rapid-deployment engagement solution to challenge industry giants.

A Boston biotech, armed with $62M and a new name, unveils a plan to build a universal model of the cell, aiming to predict and control its behavior.

As Harmony Biosciences presents at JPM, investors will scrutinize its strategy for sustaining growth beyond its star drug and advancing its rare disease pipeline.

The deal creates an end-to-end commercialization powerhouse, tackling pharma's toughest payer, reimbursement, and patient affordability challenges.

Palisade Bio's PALI-2108, a drug targeting IBD at its source, secures a key investment, offering hope for a new era of treatment with fewer side effects.

A new global study shows consumers embrace AI for product research but don't trust it for purchases, revealing a 'Confidence Economy' ruled by transparency.

Health tech firm IMVARIA, maker of an FDA-authorized AI for lung disease, has secured strategic funding from InHealth Ventures and Labcorp to expand its reach.

A new partnership brings a complex wealth-building insurance product to the digital age, offering instant decisions and no medical exams. Is this the future?

A new tri-specific antibody, IM1240, safely hits cancer cells at massive doses in preclinical studies, potentially solving a key toxicity problem in immunotherapy.

From innovative liquid-cooled LCDs to premium laser TVs with Google TV, Formovie's latest projectors signal a major play for the entire home cinema market.

A new patient app from BrightInsight and Sanofi reduced therapy discontinuation by 4%, proving digital tools can solve medicine's adherence problem.

Fresh off its 'Fierce 15' win, Recludix Pharma and its billion-dollar Sanofi pact take the spotlight with a novel oral drug for inflammatory diseases.

Vera Therapeutics' novel IgAN drug gets FDA fast-track review, promising a new at-home treatment for a debilitating autoimmune kidney disease.

With a massive $200M Series C, Soley Therapeutics is using its AI cell-sensing platform to fast-track novel cancer drugs from code to clinic.

With its revolutionary Prime Editing tech showing promise, Prime Medicine faces a pivotal moment at the J.P. Morgan conference. Can it justify its new strategy?

Kelonia Therapeutics gets the FDA green light to expand trials for its in vivo CAR-T therapy, a single-infusion treatment that could redefine cancer care.

Azitra will present its novel AI-driven skin therapies for rare diseases at Biotech Showcase, seeking crucial funding and partnerships to advance its pipeline.

New IoT solution from Clarios prevents costly trailer failures and protects cold chain goods by providing real-time battery health insights.

A new alliance aims to replace painful biopsies with high-res biology, mapping organ rejection at the cellular level to usher in a new era of personalized care.

Australian CRO Avance Clinical buys U.S. specialist LumaBridge, creating a global center of excellence to accelerate cancer therapies for biotech firms.